Michaela Dinan, PhD
Professor of Epidemiology (Chronic Diseases)DownloadHi-Res Photo
Cards
Additional Titles
Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Associate Director for Research Training and Education, Yale Cancer Center
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
About
Copy Link
Titles
Professor of Epidemiology (Chronic Diseases)
Co-Leader, Cancer Prevention and Control, Yale Cancer Center; Associate Director for Research Training and Education, Yale Cancer Center
Biography
Dr. Michaela Dinan is an Associate Professor of Epidemiology in the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She is also a member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes.
Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.
Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently leading an NCI-funded R01 study examining multi-level factors that contribute to disparities in access and adherence to oral anticancer agents for patients with kidney cancer. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.
Last Updated on April 19, 2025.
Appointments
Chronic Disease Epidemiology
ProfessorPrimaryMedical Oncology and Hematology
Associate Professor on TermSecondary
Other Departments & Organizations
- All Institutions
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- COPPER Center
- Medical Oncology and Hematology
- Public Health Data Science and Data Equity
- Yale Cancer Center
- Yale School of Public Health
- YCC Collaborative Excellence
Education & Training
- PhD
- University of North Carolina, Health Policy and Management (2011)
Research
Copy Link
Overview
Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes. She is a health services researcher with training in econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to access and quality of care, health disparities, and cost of care for cancer patients.
Medical Research Interests
Breast Neoplasms; Cancer Survivors; Carcinoma, Renal Cell; Chronic Disease; Colonic Neoplasms; Costs and Cost Analysis; Epidemiology; Risk Assessment; Urologic Neoplasms
Public Health Interests
Health Equity, Disparities, Social Determinants and Justice; Health Policy; Chronic Diseases; Aging; Cancer; Women's Health; Pharmacoepidemiology
ORCID
0000-0003-4849-4743
Research at a Glance
Yale Co-Authors
Frequent collaborators of Michaela Dinan's published research.
Publications Timeline
A big-picture view of Michaela Dinan's research output by year.
Research Interests
Research topics Michaela Dinan is interested in exploring.
Cary P Gross, MD
Michael S. Leapman, MD, MHS
Shi-Yi Wang, MD, PhD
Michael Hurwitz, MD, PhD
Timothy Robinson, MD, PhD
Ira Leeds, MD, FACS, FASCRS
162Publications
4,342Citations
Breast Neoplasms
Carcinoma, Renal Cell
Risk Assessment
Cancer Survivors
Costs and Cost Analysis
Chronic Disease
Publications
2025
Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original ResearchAltmetricUse of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Ma S, Wang S, Kunst N, Dinan M, Gross C. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. Journal Of Clinical Oncology 2025, 43: 11155-11155. DOI: 10.1200/jco.2025.43.16_suppl.11155.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerTargeted therapyLung cancerTargetable alterationsGenomic profilingUsefulness of targeted therapyUS cancer clinicsFirst-line treatmentCohort of patientsClinico-genomic databaseNCCN guidelinesIdentified patientsPatient populationFDA approvalTreatment selectionPatientsCancer clinicClinical guidelinesTherapyCancerLimited dataTT useFDA approval statusFactors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis.
Forman R, Wang R, Yasin F, Kwaramba T, Lacy J, Ma X, Dinan M. Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis. Journal Of Clinical Oncology 2025, 43: 11168-11168. DOI: 10.1200/jco.2025.43.16_suppl.11168.Peer-Reviewed Original ResearchConceptsMetastatic colon cancerNon-intensive therapyNational Comprehensive Cancer NetworkPoor performance statusIntensive therapyFlatiron Health electronic health record-derived deidentified databaseColon cancerIntensive first-line therapyUndertreatment of older patientsNational Comprehensive Cancer Network guidelinesOdds ratioAssociated with treatment choiceFirst-line therapyAssociated with female sexComprehensive Cancer NetworkRetrospective cohort studyYear of diagnosisShorter overall survivalNon-frail patientsOlder ageNon-frailMultivariate logistic regressionEstimate odds ratiosAssociated with receiptTreatment intensityRisk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
Kwaramba T, Westvold S, Long J, Hyslop T, Silber A, Lustberg M, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Dinan M. Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors. Journal Of Clinical Oncology 2025, 43: 1642-1642. DOI: 10.1200/jco.2025.43.16_suppl.1642.Peer-Reviewed Original ResearchConceptsSurvivors of breastRectal cancer survivorsCancer survivorsYears post-diagnosisPost-diagnosisOlder survivorsScreen-detectedSEER-MedicareLong-term cancer survivorsNon-screened cancersLong-term breastStage I-III cancerProstate cancer survivorsIndex cancer diagnosisContinuous Medicare Parts ASEER-Medicare dataModifiable risk factorsMedicare Part ADiagnosis of SPMSurvivorship careSEER-Medicare databaseSurvivorship cohortScreening guidelinesAssociated with shorter timeIndex cancerScreening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, PMCID: PMC12000969, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stagesBPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era.
Wang X, Long J, Rothen J, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Wang S, Kunst N, Ma S, Huang S, Gross C, Dinan M. BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 40154428, DOI: 10.6004/jnccn.2024.7205.Peer-Reviewed Original ResearchOff-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma
McManus H, Long J, Westvold S, Leapman M, Hurwitz M, Mitchell A, Pollack C, Gross C, Dinan M. Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2025, 23: 102330. PMID: 40186898, PMCID: PMC12084128, DOI: 10.1016/j.clgc.2025.102330.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsMetastatic renal cell carcinomaImmune checkpoint inhibitorsFood and Drug AdministrationRenal cell carcinomaOff-labelCell carcinomaOlder patientsImmune checkpoint inhibitor useFood and Drug Administration approvalFirst-line immunotherapyMultivariate logistic regressionOff-label useCo-morbid conditionsCheckpoint inhibitorsFirst-lineCo-morbiditiesDrug AdministrationPatientsCo-morbidityPostapproval settingLogistic regressionCarcinomaDemographic characteristicsPostapprovalPostapproval periodPersonalized frailty risk assessment in long-term survivors of colorectal cancer.
Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.Peer-Reviewed Original ResearchConceptsRectal cancer survivorsCancer survivorsElixhauser Comorbidity IndexLong-term survivors of colorectal cancerSurvivors of colorectal cancerClinical prediction modelStage I-III colonCancer diagnosisGastrointestinal cancer survivorsYear 4Area-level povertyAssociated with reduced qualityRisk of frailtyProportion of residentsOnset of frailtyPredictors of frailtyFederal poverty lineIncreased risk of deathAdministrative claims codesSurvivorship managementRisk of deathRetrospective cohort studyAssociated with shorter timePatient raceSevere frailtyPredictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence.
Yasin F, Westvold S, Long J, Fan J, Hyslop T, Leeds I, Cecchini M, Gross C, Dinan M. Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence. Journal Of Clinical Oncology 2025, 43: 66-66. DOI: 10.1200/jco.2025.43.4_suppl.66.Peer-Reviewed Original ResearchConceptsCRC-specific mortalityAll-Cause MortalityCancer diagnosisColorectal cancerLong-term CRC survivorsNon-cancer related conditionsNon-metastatic colorectal cancerSEER-MedicareRisk of all-cause mortalityRecurrence of colorectal cancerColon cancerSEER-Medicare populationYear 5CRC survivorsSEER-Medicare databaseSurvivorship careRectal cancerFollow-up accountsColorectal cancer recurrenceMultiple co-morbiditiesMedicare claimsRetrospective cohort studyFine-Gray modelEstimate cumulative incidencePrimary risk factor
News & Links
Copy Link
Media
News
- August 08, 2025
Yale Cancer Center’s CRTEC Program Launches Future Deaf Scientists Internship
- July 31, 2025
Boosting access to kidney cancer treatments
- May 06, 2025
Genetic Test Underused in Cancer Care
- May 05, 2025
Older Women May Benefit From Regular Mammograms
Get In Touch
Copy Link
Contacts
Academic Office Number
Mailing Address
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
Locations
Ste 444
Academic Office
60 College Street
New Haven, CT 06510